FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077881463> ?p ?o ?g. }

• W2077881463 endingPage "42" @default.
• W2077881463 startingPage "36" @default.
• W2077881463 abstract "Permanent prostate implant brachytherapy (PPI), three-dimensional conformal radiotherapy (3D-CRT), and conformal proton beam radiotherapy (CPBRT) are used in the treatment of localized prostate cancer, although no head-to-head trials have compared these modalities. We studied the biochemical control (biochemical no evidence of disease [bNED]) and prostate-specific antigen (PSA) nadir achieved with contemporary PPI, and evaluated it against 3D-CRT and CPBRT.A total of 249 patients were treated with PPI at the University of California, San Francisco, and the outcomes were compared with those from a 3D-CRT cohort and the published results of a high-dose CPBRT boost (CPBRTB) trial. For each comparison, subsets of the PPI cohort were selected with patient and disease criteria similar to those of the reference group.With a median follow-up of 5.3 years, the bNED rate at 5 and 7 years achieved with PPI was 92% and 86%, respectively, using the American Society for Therapeutic Radiology and Oncology (ASTRO) definition, and 93% using the PSA nadir plus 2 ng/mL definition. Using the ASTRO definition, a 5-year bNED rate of 78% was achieved for the 3D-CRT patients compared with 94% for a comparable PPI subset and 93% vs. 92%, respectively, using the PSA nadir plus 2 ng/mL definition. The median PSA nadir for patients treated with PPI and 3D-CRT was 0.10 and 0.40 ng/mL, respectively (p < .0001). For the CPBRT comparison, the 5-year bNED rate after a CPBRTB was 91% using the ASTRO definition vs. 93% for a similar group of PPI patients. A greater proportion of PPI patients achieved a lower PSA nadir compared with those achieved in the CPBRTB trial (PSA nadir < or =0.5 ng/mL, 91% vs. 59%, respectively).We have demonstrated excellent outcomes in low- to intermediate-risk patients treated with PPI, suggesting at least equivalent 5-year bNED rates and a greater proportion of men achieving lower PSA nadirs compared with 3D-CRT or CPBRTB." @default.
• W2077881463 created "2016-06-24" @default.
• W2077881463 creator A5011810130 @default.
• W2077881463 creator A5016481078 @default.
• W2077881463 creator A5018226548 @default.
• W2077881463 creator A5021162147 @default.
• W2077881463 creator A5022388474 @default.
• W2077881463 creator A5039728792 @default.
• W2077881463 creator A5045162411 @default.
• W2077881463 creator A5056873120 @default.
• W2077881463 creator A5060643578 @default.
• W2077881463 creator A5089472018 @default.
• W2077881463 date "2010-01-01" @default.
• W2077881463 modified "2023-10-09" @default.
• W2077881463 title "Equivalent Biochemical Control and Improved Prostate-Specific Antigen Nadir After Permanent Prostate Seed Implant Brachytherapy Versus High-Dose Three-Dimensional Conformal Radiotherapy and High-Dose Conformal Proton Beam Radiotherapy Boost" @default.
• W2077881463 cites W1968618135 @default.
• W2077881463 cites W1969027862 @default.
• W2077881463 cites W1969753482 @default.
• W2077881463 cites W1979665150 @default.
• W2077881463 cites W1985014098 @default.
• W2077881463 cites W1987213359 @default.
• W2077881463 cites W1989920747 @default.
• W2077881463 cites W1991870815 @default.
• W2077881463 cites W1994364707 @default.
• W2077881463 cites W1996809772 @default.
• W2077881463 cites W1997610387 @default.
• W2077881463 cites W2008898405 @default.
• W2077881463 cites W2009493512 @default.
• W2077881463 cites W2012457048 @default.
• W2077881463 cites W2029026992 @default.
• W2077881463 cites W2047568196 @default.
• W2077881463 cites W2054899405 @default.
• W2077881463 cites W2069668670 @default.
• W2077881463 cites W2083074823 @default.
• W2077881463 cites W2085907209 @default.
• W2077881463 cites W2088876512 @default.
• W2077881463 cites W2089983916 @default.
• W2077881463 cites W2093867637 @default.
• W2077881463 cites W2097532477 @default.
• W2077881463 cites W2098443648 @default.
• W2077881463 cites W2101094062 @default.
• W2077881463 cites W2114681200 @default.
• W2077881463 cites W2117204935 @default.
• W2077881463 cites W2117792530 @default.
• W2077881463 cites W2126645707 @default.
• W2077881463 cites W2129252368 @default.
• W2077881463 cites W2135435808 @default.
• W2077881463 cites W2137568839 @default.
• W2077881463 cites W2150871301 @default.
• W2077881463 cites W2158090738 @default.
• W2077881463 cites W2159404318 @default.
• W2077881463 cites W2161324454 @default.
• W2077881463 cites W2172038823 @default.
• W2077881463 cites W30869299 @default.
• W2077881463 cites W4243034093 @default.
• W2077881463 doi "https://doi.org/10.1016/j.ijrobp.2009.01.029" @default.
• W2077881463 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19409729" @default.
• W2077881463 hasPublicationYear "2010" @default.
• W2077881463 type Work @default.
• W2077881463 sameAs 2077881463 @default.
• W2077881463 citedByCount "45" @default.
• W2077881463 countsByYear W20778814632012 @default.
• W2077881463 countsByYear W20778814632013 @default.
• W2077881463 countsByYear W20778814632014 @default.
• W2077881463 countsByYear W20778814632015 @default.
• W2077881463 countsByYear W20778814632016 @default.
• W2077881463 countsByYear W20778814632017 @default.
• W2077881463 countsByYear W20778814632018 @default.
• W2077881463 countsByYear W20778814632019 @default.
• W2077881463 countsByYear W20778814632021 @default.
• W2077881463 countsByYear W20778814632023 @default.
• W2077881463 crossrefType "journal-article" @default.
• W2077881463 hasAuthorship W2077881463A5011810130 @default.
• W2077881463 hasAuthorship W2077881463A5016481078 @default.
• W2077881463 hasAuthorship W2077881463A5018226548 @default.
• W2077881463 hasAuthorship W2077881463A5021162147 @default.
• W2077881463 hasAuthorship W2077881463A5022388474 @default.
• W2077881463 hasAuthorship W2077881463A5039728792 @default.
• W2077881463 hasAuthorship W2077881463A5045162411 @default.
• W2077881463 hasAuthorship W2077881463A5056873120 @default.
• W2077881463 hasAuthorship W2077881463A5060643578 @default.
• W2077881463 hasAuthorship W2077881463A5089472018 @default.
• W2077881463 hasConcept C121608353 @default.
• W2077881463 hasConcept C126322002 @default.
• W2077881463 hasConcept C126838900 @default.
• W2077881463 hasConcept C126894567 @default.
• W2077881463 hasConcept C127413603 @default.
• W2077881463 hasConcept C141071460 @default.
• W2077881463 hasConcept C146978453 @default.
• W2077881463 hasConcept C19269812 @default.
• W2077881463 hasConcept C2775908122 @default.
• W2077881463 hasConcept C2776235491 @default.
• W2077881463 hasConcept C2777416452 @default.
• W2077881463 hasConcept C2780192828 @default.
• W2077881463 hasConcept C2781406297 @default.
• W2077881463 hasConcept C2781411149 @default.
• W2077881463 hasConcept C2989005 @default.
• W2077881463 hasConcept C509974204 @default.

• next